TY - JOUR
T1 - Erratum to
T2 - Fractionated vs. single-fraction stereotactic radiotherapy in patients with vestibular schwannoma: Hearing preservation and patients’ self-reported outcome based on an established questionnaire (Strahlentherapie und Onkologie, (2016), 10.1007/s00066-016-1070-0)
AU - Kessel, Kerstin A.
AU - Fischer, H.
AU - Vogel, M. M.
AU - Oechsner, M.
AU - Bier, H.
AU - Meyer, B.
AU - Combs, S. E.
N1 - Publisher Copyright:
© 2016, Springer-Verlag Berlin Heidelberg.
PY - 2017/2/1
Y1 - 2017/2/1
N2 - Unfortunately, a typing error occurred in the results section of the abstract of the article “Fractionated vs. singlefraction stereotactic radiotherapy in patients withvestibular schwannoma”.The mean overall survival after stereotactic radiotherapy was 13.1 years and not 31.1 years. The correct sentence of the results section in the abstract reads as follows: Mean overall survival (OS) after RT was 13.1 years, with 94 and 87% survival at 5 and 10 years, respectively The same applies to the German abstract.The correct sentence of the section “Ergebnisse” in the abstract reads as follows:Das mediane Follow-up nach RT betrug 7,5 Jahre (Spanne 0–14,4 Jahre), das mittlere Gesamtüberleben (OS) nach RT 13,1 Jahre, mit Überlebensraten von 94 und 87% nach 5 und 10 Jahren und das mittlere progressionsfreie Überleben (PFS) 13,3 Jahre, mit einem 5- und 10-Jahres- PFS von 92%. No further typing error occurred in the article proper. We apologize for any inconvenience caused.
AB - Unfortunately, a typing error occurred in the results section of the abstract of the article “Fractionated vs. singlefraction stereotactic radiotherapy in patients withvestibular schwannoma”.The mean overall survival after stereotactic radiotherapy was 13.1 years and not 31.1 years. The correct sentence of the results section in the abstract reads as follows: Mean overall survival (OS) after RT was 13.1 years, with 94 and 87% survival at 5 and 10 years, respectively The same applies to the German abstract.The correct sentence of the section “Ergebnisse” in the abstract reads as follows:Das mediane Follow-up nach RT betrug 7,5 Jahre (Spanne 0–14,4 Jahre), das mittlere Gesamtüberleben (OS) nach RT 13,1 Jahre, mit Überlebensraten von 94 und 87% nach 5 und 10 Jahren und das mittlere progressionsfreie Überleben (PFS) 13,3 Jahre, mit einem 5- und 10-Jahres- PFS von 92%. No further typing error occurred in the article proper. We apologize for any inconvenience caused.
UR - http://www.scopus.com/inward/record.url?scp=85006093298&partnerID=8YFLogxK
U2 - 10.1007/s00066-016-1087-4
DO - 10.1007/s00066-016-1087-4
M3 - Comment/debate
C2 - 27981336
AN - SCOPUS:85006093298
SN - 0179-7158
VL - 193
SP - 171
JO - Strahlentherapie und Onkologie
JF - Strahlentherapie und Onkologie
IS - 2
ER -